The collaboration with Lonza, a reputable company in the biotech space, to develop and optimize a method for utilizing Neuron-Derived Exosomes (NDEs) could provide NeuroSense with a significant competitive advantage in the neurodegenerative disease treatment market. This partnership is likely to enhance the company's research capabilities and potentially speed up the development and commercialization of its PrimeC treatment, positively impacting investor sentiment and the company's stock price in the short term.